Mar 20 |
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
Mar 20 |
TFF Pharma gains after portfolio shakeup
|
Mar 20 |
TFF Pharmaceuticals Announces Update on Clinical Programs
|
Mar 14 |
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
|
Jan 24 |
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference
|
Dec 19 |
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
|
Dec 18 |
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC
|
Dec 15 |
TFF Pharmaceuticals announces 1-for-25 reverse stock split
|
Dec 15 |
TFF Pharmaceuticals Announces Reverse Stock Split
|
Nov 30 |
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors
|